At present, there is no evidence that a longer diagnosis-to-NAT interval leads to disease progression or worse survival in patients with esophageal cancer, which may be due to the limited delay before NAT, and the unadjusted impact of the NAT-to-surgery interval could also be a contributing factor.14,21 However, as mentioned earlier, multiple studies have shown that longer nCRT-to-surgery interval was associated with poorer survival, probably due to disease progression.42,46,47. The gene discussed is BRD2; the disease is esophageal cancer.